Liontrust Investment Partners LLP Takes $557,000 Position in Medpace Holdings, Inc. $MEDP

Key Points

• Liontrust Investment Partners LLP invested approximately $557,000 in Medpace Holdings, acquiring 1,828 shares during the first quarter.
• Medpace's CEO, August J. Troendle, sold 48,487 shares for over $21 million, representing a 4.80% reduction in his holdings.
• The stock has seen a 12-month high of $501.30 and a low of $250.05, with a current market capitalization of $12.86 billion.

Liontrust Investment Partners LLP purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,828 shares of the company's stock, valued at approximately $557,000.

Several other institutional investors have also recently added to or reduced their stakes in MEDP. Barclays PLC increased its position in Medpace by 42.4% in the 4th quarter. Barclays PLC now owns 28,166 shares of the company's stock valued at $9,359,000 after acquiring an additional 8,385 shares during the period. Mariner LLC increased its position in Medpace by 42.3% during the 4th quarter. Mariner LLC now owns 2,825 shares of the company's stock worth $939,000 after purchasing an additional 840 shares during the period. Marshall Wace LLP acquired a new position in Medpace during the 4th quarter worth approximately $4,795,000. Commerce Bank increased its position in Medpace by 15.9% during the 4th quarter. Commerce Bank now owns 2,058 shares of the company's stock worth $684,000 after purchasing an additional 283 shares during the period. Finally, GeoWealth Management LLC increased its position in Medpace by 27.8% during the 4th quarter. GeoWealth Management LLC now owns 285 shares of the company's stock worth $95,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Activity at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of the company's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 48,487 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the sale, the chief executive officer owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. The trade was a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 112,788 shares of company stock worth $51,018,354. Company insiders own 20.30% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on MEDP shares. Cowen cut Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. UBS Group cut Medpace from a "neutral" rating to a "sell" rating and boosted their target price for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. Robert W. Baird upped their price target on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. TD Cowen restated a "sell" rating and issued a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Finally, Barclays upped their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Reduce" and an average price target of $406.60.

Medpace Stock Performance

MEDP stock traded down $0.77 on Tuesday, reaching $462.14. The company had a trading volume of 323,418 shares, compared to its average volume of 455,060. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30. The company's fifty day moving average is $369.30 and its 200 day moving average is $332.71. The company has a market cap of $12.98 billion, a P/E ratio of 34.36, a PEG ratio of 2.88 and a beta of 1.42.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same quarter in the prior year, the company earned $2.75 EPS. Medpace's revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.